DEA lifts production quotas to ease injectable opioid shortage
Opioid shortage timeline
March 2017: Drug manufacturers deadline to file controlled-substance quota requests with the Drug Enforcement Administration for fiscal 2018July 20, 2017: Pfizer notifies customers that it will not be able to meet the demand for injectable opioids by the end of the monthJan. 1, 2018: West-Ward Pharmaceuticals and Fresenius Kabi request an additional allocation given the shortage. The request is only partially granted, and it takes until mid-February and mid-March to make it official because the DEA had to send out diversion investigators to reconcile inventory reporting issuesJan. 31, 2018: Pfizer stops all shipments of finished injectable opioids due to a third-party supplier issueMarch 12, 2018: Senate Minority Leader Chuck Schumer (D-N.Y.) asks the DEA to lift production quotas that are limiting the supply of legal opioids used at hospitals nationwideApril 6, 2018: Pfizer sends another letter that it has resumed some production of injectable opioids. The first batch is expected to reach wholesalers in JulySecond quarter 2019: Pfizer expected to resume full production of the injectable painkillers
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.